Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia

H Volkmann, J Nørregaard, Søren Jacobsen, B Danneskiold-Samsøe, G Knoke, D Nehrdich

51 Citationer (Scopus)

Abstrakt

The objective of this study was to test the efficacy of intravenously administered S-adenosyl-L-methionine (SAMe) in patients with fibromyalgia (FM). Thirty-four out-patients with fibromyalgia symptoms received SAMe 600 mg i.v. or placebo daily for 10 days in a cross-over trial. There was no significant difference in improvement in the primary outcome: tender point change between the two treatment groups. There was a tendency towards statistical significance in favour of SAMe on subjective perception of pain at rest (p = 0.08), pain on movement (p = 0.11), and overall well-being (p = 0.17) and slight improvement only on fatigue, quality of sleep, morning stiffness, and on the Fibromyalgia Impact Questionnaire for pain. No effect could be observed on isokinetic muscle strength, Zerrsen self-assessment questionnaire, and the face scale. No effect of SAMe in patients with FM was found in this short term study.
OriginalsprogEngelsk
TidsskriftScandinavian Journal of Rheumatology
Vol/bind26
Udgave nummer3
Sider (fra-til)206-11
Antal sider6
ISSN0300-9742
StatusUdgivet - 1997

Fingeraftryk

Dyk ned i forskningsemnerne om 'Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia'. Sammen danner de et unikt fingeraftryk.

Citationsformater